XTL BIOPHARMA (Germany) Today

Equity ratings for XTL BIOPHARMA ADR are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 9th of September 2019 and ending today, the 30th of July 2021. Click here to learn more.
XTL BIOPHARMA ADR cannot be verified against its exchange. It appears that XTL BIOPHARMA is not available for investing at the moment. Please verify the symbol is currently traded on Frankfurt Stock Exchange. If you still believe the symbol you are trying to look up is valid please let us know and we will check it as soon as possible.
Refresh

XTL BIOPHARMA Stock Profile

XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. XTL Biopharmaceuticals Ltd. was founded in 1993 and is headquartered in Ramat Gan, Israel. XTL Biopharmaceutica is traded on Frankfurt Stock Exchange in Germany.. The public information regarding XTL BIOPHARMA ADR's current market price is not available at this time.
XTL BIOPHARMA ADR is not yet fully synchronised with the market data
XTL BIOPHARMA ADR has some characteristics of a very speculative penny stock
XTL BIOPHARMA ADR has high likelihood to experience some financial distress in the next 2 years
XTL BIOPHARMA ADR has accumulated about 5.06 M in cash with (816 K) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.98.
Legal NameXTL BIOPHARMA ADR
Macroaxis Advice
Unlike general analyst consensus, Macroaxis buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of XTL BIOPHARMA's available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Not RatedUndervalued
XTL BIOPHARMA ADR (H2K2) is traded on Frankfurt Stock Exchange in Germany . The company currently falls under 'Nano-Cap' category with current market capitalization of 9.68 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate XTL BIOPHARMA's market, we take the total number of its shares issued and multiply it by XTL BIOPHARMA's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities. XTL BIOPHARMA ADR operates under Healthcare sector and is part of Biotechnology industry. The entity has 5.14 M outstanding shares. XTL BIOPHARMA ADR has accumulated about 5.06 M in cash with (816 K) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.98.
Check XTL BIOPHARMA Probability Of Bankruptcy

XTL BIOPHARMA Stock Against Markets

Picking the right benchmark for XTL BIOPHARMA stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in XTL BIOPHARMA stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for XTL BIOPHARMA is critical whether you are bullish or bearish towards XTL BIOPHARMA ADR at a given time.
XTL BIOPHARMA ADR cannot be verified against its exchange. It appears that XTL BIOPHARMA is not available for investing at the moment. Please verify the symbol is currently traded on Frankfurt Stock Exchange. If you still believe the symbol you are trying to look up is valid please let us know and we will check it as soon as possible.
Refresh

Try Other Stock Suggestions

View Currently Related Equities

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with XTL BIOPHARMA stock to make a market-neutral strategy. Peer analysis of XTL BIOPHARMA could also be used in its relative valuation, which is a method of valuing XTL BIOPHARMA by comparing valuation metrics with similar companies.
Check out Risk vs Return Analysis. Note that the XTL BIOPHARMA ADR information on this page should be used as a complementary analysis to other XTL BIOPHARMA's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.

Other Tools for XTL BIOPHARMA Stock

When running XTL BIOPHARMA ADR price analysis, check to measure XTL BIOPHARMA's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy XTL BIOPHARMA is operating at the current time. Most of XTL BIOPHARMA's value examination focuses on studying past and present price action to predict the probability of XTL BIOPHARMA's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move XTL BIOPHARMA's price. Additionally, you may evaluate how the addition of XTL BIOPHARMA to your portfolios can decrease your overall portfolio volatility.
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Go
Bond Directory
Find actively traded corporate debentures issued by US companies
Go
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Go
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Go
Focused Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Go
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Go